Zobrazeno 1 - 10
of 420
pro vyhledávání: '"bamlanivimab"'
Autor:
Dipak R. Patel, Lisa Macpherson, Martin Bohm, Himanshu Upadhyaya, Carmen Deveau, Ajay Nirula, Paul Klekotka, Mark Williams, Matthew M. Hufford
Publikováno v:
Infectious Diseases and Therapy, Vol 13, Iss 10, Pp 2123-2134 (2024)
Abstract Introduction The monoclonal antibody therapies bamlanivimab (BAM) + etesevimab (ETE) received emergency use authorization (EUA) from the US Food and Drug Administration (February 9, 2021) for treatment of mild-to-moderate COVID-19. The EUA o
Externí odkaz:
https://doaj.org/article/cf567da4bb5443c981f49175bf36b985
Autor:
Marc-Kendy Paul, Manish Choudhary, Amy Heaps, Rinki Deo, Daniela Moisi, Kelley Gordon, John Mellors, Carlee Moser, Paul Klekotka, Alan Landay, Judith Currier, Joseph Eron, Kara Chew, Davey Smith, Scott Sieg, Urvi Parikh, Jonathan Li
Publikováno v:
Pathogens and Immunity, Vol 9, Iss 2 (2024)
Background: Anti-SARS-CoV-2 monoclonal antibodies (mAbs) have played a key role as an antiviral against SARS-CoV-2, but there is a potential for resistance to develop. The interplay between host antibody responses and the development of monoclonal an
Externí odkaz:
https://doaj.org/article/bdccb63bddb5442fabd3c42a04dba847
Publikováno v:
Infectious Diseases and Therapy, Vol 13, Iss 2, Pp 401-411 (2024)
Abstract Introduction Treatment with monoclonal antibodies provides rapid, passive immunity and may stop COVID-19 disease progression. The study evaluated the effect of bamlanivimab (BAM) or BAM + etesevimab (ETE)/sotrovimab compared to placebo on SA
Externí odkaz:
https://doaj.org/article/071b45585d364709905a48a4f2a3cac4
Autor:
Himanshu P. Upadhyaya, Jenny Y. Chien, Amanda J. Long, Martin S. Bohm, Nicole L. Kallewaard, Lisa F. Macpherson, Dipak R. Patel, Matthew M. Hufford, Constance J. Krull, Jocelyn Y. Ang, Peter Chen, William J. Muller, Jeffrey A. Potts, Timothy Quinn, Mark Williams, BLAZE-1 Investigators
Publikováno v:
Infectious Diseases and Therapy, Vol 12, Iss 7, Pp 1861-1873 (2023)
Abstract Introduction Bamlanivimab and etesevimab (BAM + ETE) are monoclonal antibodies (mAbs) effective in reducing COVID-19-related hospitalizations and all-cause mortality in adult participants at increased risk for severe disease. We present phar
Externí odkaz:
https://doaj.org/article/4a8e4f959324473bb550800f3098224f
Autor:
Martin Heller, Clara Henrici, Judith Büttner, Sebastian Leube, Isabelle Treske, Petra Pospischil, Michael Doll, Ilka Schanz, Agnes Hallier, Eva Herrmann, Michael Schmidt, Christoph Sarrazin
Publikováno v:
International Journal of Infectious Diseases, Vol 129, Iss , Pp 260-265 (2023)
Objectives: In this early retrospective cohort study, a total of 26 patients with SARS-CoV-2 were treated with bamlanivimab or casirivimab/imdevimab, and the reduction of the viral load associated with the developed clinical symptoms was analyzed. Me
Externí odkaz:
https://doaj.org/article/b89c38cffdf0416ba36498e3a5265dba
Monoclonal Antibody Therapy for COVID-19: A Retrospective Observational Study at a Regional Hospital
Autor:
Judith Pannier, Norbert Nass, Mohamad-Kamal Yaakoub, Florian Michael Maria Stelzner, Susann Veit, Margarita Kalomoiri, Mahdi Yassine, Gerhard Behre
Publikováno v:
Infectious Disease Reports, Vol 15, Iss 1, Pp 125-131 (2023)
Background: Monoclonal antibodies represent one option for treatment of COVID-19 early after infection. Although large clinical trials have been successfully conducted, real world data are needed to obtain a realistic assessment of the assumed effect
Externí odkaz:
https://doaj.org/article/b1d6137d5f0f40ada547d2b6a54e2730
Autor:
Rajapillai L. I. Pillai, Caroline Dziel, Stephanie Vogel, Frank Szczerba, Weijen W. Chang, Ingrid Y. Camelo, Armando Paez
Publikováno v:
Journal of Medical Case Reports, Vol 17, Iss 1, Pp 1-3 (2023)
Abstract Background Bamlanivimab and etesevimab had been granted emergency use authorization in children under 12 years who are at risk of progression from mild/moderate coronavirus disease 2019 to severe disease and hospitalization. Case report We r
Externí odkaz:
https://doaj.org/article/085619dfe30d4b21b80e738faa27afdf
Autor:
Yu-Lin Tai, Ming-Dar Lee, Hsin Chi, Nan-Chang Chiu, Wei-Te Lei, Shun-Long Weng, Lawrence Yu-Min Liu, Chung-Chu Chen, Shih-Yu Huang, Ya-Ning Huang, Chien-Yu Lin
Publikováno v:
PeerJ, Vol 11, p e15344 (2023)
Background Coronavirus disease 2019 (COVID-19) has caused an enormous loss of life worldwide. The spike protein of the severe acute respiratory syndrome coronavirus 2 is the cause of its virulence. Bamlanivimab, a recombinant monoclonal antibody, has
Externí odkaz:
https://doaj.org/article/341a5f11202d4035a0b49a06a157474e
Autor:
Robert W. Cross, Christopher M. Wiethoff, Patricia Brown-Augsburger, Shawn Berens, Jamie Blackbourne, Ling Liu, Xiaohua Wu, Jonathan Tetreault, Carter Dodd, Ramtin Sina, Derrick R. Witcher, Deanna Newcomb, Denzil Frost, Angela Wilcox, Viktoriya Borisevich, Krystle N. Agans, Courtney Woolsey, Abhishek N. Prasad, Daniel J. Deer, Joan B. Geisbert, Natalie S. Dobias, Karla A. Fenton, Beth Strifler, Philip Ebert, Richard Higgs, Anne Beall, Sumit Chanda, Laura Riva, Xin Yin, Thomas W. Geisbert
Publikováno v:
Pathogens, Vol 12, Iss 12, p 1408 (2023)
As part of the non-clinical safety package characterizing bamlanivimab (SARS-CoV-2 neutralizing monoclonal antibody), the risk profile for antibody-dependent enhancement of infection (ADE) was evaluated in vitro and in an African green monkey (AGM) m
Externí odkaz:
https://doaj.org/article/f7f4761387234185a8923bd4c6b15ef6
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.